Dabigatran Etexilate Is Effective And Safe For The Extended Prevention Of Venous Thromboembolism Following Total Hip Replacement
BI Eriksson, OE Dahl, N Rosencher, et al.
Pharmacokinetics (Pk) And Pharmacodynamics (Pd) Of Rivaroxaban: A Comparison Of Once- And Twice-Daily Dosing In Patients Undergoing Total Hip Replacement (Thr)
BI Eriksson, F Misselwitz, W Mueck
Exposure-Clinical Outcome Modeling And Simulation To Facilitate Dose Selection Of Apixaban In Subjects Undergoing Elective Total Knee Replacement Surgery
Y Feng, LY Li, A Shenker, M Pfister, Z Yu
Dabigatran Etexilate Versus Enoxaparin In Preventing Venous Thromboembolism Following Total Knee Arthroplasty
RJ Friedman, JA Caprini, PC Comp, BL Davidson, et al
Apixaban, An Oral Direct Factor Xa Inhibitor: Multiple-Dose Safety, Pharmacokinetics, And Pharmacodynamics In Healthy Subjects
C Frost, Z Yu, K Moore, et al.
Apixaban, An Oral Direct, Factor Xa Inhibitor: Single-Dose Safety, Pharmacokinetics And Pharmacodynamics In Healthy Subjects
C Frost, Z Yu, S Nepal, R Mosqueda-Garcia, A Shenker
Effect Of Hepatic Impairment On The Pharmacokinetics, Pharmacodynamics And Tolerability Of Rivaroxaban – An Oral, Direct Factor Xa Inhibitor
A Halabi, D Kubitza, M Zuehlsdorf, et al.
Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – Has No Clinically Relevant Interaction With Acetylsalicylic Acid Or Naproxen
D Kubitza, M Becka, W Mueck, M Zuehlsdorf
The Effect Of Age And Gender On The Pharmacology And Safety Of The Oral, Direct Factor Xa Inhibitor Rivaroxaban
D Kubitza, M Becka, W Mueck, M Zuehlsdorf
Rivaroxaban: An Oral, Direct Factor Xa Inhibitor For The Prevention Of Venous Thromboembolism In Total Knee Replacement Surgery – Results Of The Record 3 Study
MR Lassen, AG Turpie, N Rosencher, et al.
Inhibition Of Measured Thrombin Generation In Human Plasma By Apixaban: A Predictive Mathematical Model Based On Experimentally Determined Rate Constants
JM Luettgen, Z Wang, DA Seiffert, et al.
Three Different Patterns Of Calibrated Automated Thrombogram Obtained With Hirudin, Melagatran, Dabigatran, Argatroban, Fondaparinux And Danaparoïd
MM Samama, L Le Flem, C Guinet, F Depasse
Coadministration Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate And Diclofenac Has Little Impact On The Pharmacokinetics Of Either Drug
J Stangier, H Stähle, K Rathgen, K Reseski, T Körnicke
Coadministration Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate And Atorvastatin Has Little Impact On The Pharmacokinetics And Pharmacodynamics Of Either Drug
J Stangier, H Stähle, K Rathgen, K Reseski, T Körnicke
No Interaction Of The Oral Direct Thrombin Inhibitor Dabigatran Etexilate And Digoxin
J Stangier, H Stähle, K Rathgen, K Reseski, T Körnicke
Pharmacokinetics And Pharmacodynamics Of Dabigatran Etexilate In Subjects With Moderate Hepatic Impairment
J Stangier, K Rathgen, H Stähle, K Shakeri-Nejad
Rivaroxaban – An Oral, Direct Factor Xa Inhibitor – Binds Rapidly To Factor Xa
A Tersteegen, N Burkhardt
Recombinant Factor Viia Partially Reverses The Anticoagulant Effect Of High-Dose Rivaroxaban – A Novel, Oral, Direct Factor Xa Inhibitor – In Rats
H Tinel, J Huetter, E Perzborn
Potential Of The Factor Xa Inhibitor Rivaroxaban For The Anticoagulation Management Of Patients With Heparin-Induced Thrombocytopenia
JM Walenga, WP Jeske, M Prechel, et al.